{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T10:10:03Z","timestamp":1756375803653,"version":"3.44.0"},"reference-count":15,"publisher":"BMJ","issue":"4","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2025,4,8]]},"published-print":{"date-parts":[[2025,4]]},"abstract":"<jats:p>Pancreatic cancer is a malignancy with poor prognosis and overall poor response to systemic therapy. Moreover, patients with locally advanced or unresectable tumours have historically worse outcomes compared with those with earlier stages of disease. We report a case of a female patient in the fourth decade with locally advanced pancreatic adenocarcinoma, who received 12 cycles modified FOLFIRINOX (mFOLFIRINOX: fluorouracil\/leucovorin\/irinotecan\/oxaliplatin) chemotherapy, followed by pancreaticoduodenectomy, resulting in a near complete pathological response after definitive surgical treatment. Given the lack of indication for adjuvant therapy, she is considered in remission. The case demonstrates that potentially curative surgical resection can be a viable and sought-after treatment option for patients with locally advanced and\/or metastatic pancreatic cancer, as it is not readily available for many patients due to the disease\u2019s aggressive nature and presence of advanced stage at diagnosis. It holds meaningful implications for clinical practice and promotes considerations in future advancements in treatment strategies.<\/jats:p>","DOI":"10.1136\/bcr-2024-264212","type":"journal-article","created":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T23:35:21Z","timestamp":1744932921000},"page":"e264212","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Locally advanced pancreatic cancer treated with surgical resection after chemotherapy"],"prefix":"10.1136","volume":"18","author":[{"given":"Soobin Serena","family":"Lee","sequence":"first","affiliation":[{"name":"University of Miami, University of Miami, Leonard M. Miller School of Medicine, Miami, Florida, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samuel A","family":"Kareff","sequence":"additional","affiliation":[{"name":"Baptist Health South Florida, Lynn Cancer Institute, Boca Raton, Florida, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raleigh A","family":"Fatoki","sequence":"additional","affiliation":[{"name":"Sylvester Cancer Center, University of Miami Health System, Miami, Florida, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2025,4,17]]},"reference":[{"key":"2025082802323644000_18.4.e264212.1","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.862600","article-title":"Case Report: A Case of Locally Advanced Pancreatic Cancer Which Achieved Progression Free for Over 12 Months by Subsequent Therapy with Anlotinib Hydrochloride Plus Tegafur-Gimeracil-Oteracil Potassium (TS-1)","volume":"12","author":"Luo","year":"2022","journal-title":"Front Oncol"},{"key":"2025082802323644000_18.4.e264212.2","doi-asserted-by":"crossref","DOI":"10.1186\/s12943-019-1008-0","article-title":"The microbiota and microbiome in pancreatic cancer: more influential than expected","volume":"18","author":"Wei","year":"2019","journal-title":"Mol Cancer"},{"key":"2025082802323644000_18.4.e264212.3","unstructured":"American cancer society survival rates for pancreatic cancer. Available: https:\/\/www.cancer.org\/cancer\/types\/pancreatic-cancer\/detection-diagnosis-staging\/survival-rates.html [Accessed 30 Oct 2024]."},{"key":"2025082802323644000_18.4.e264212.4","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.3390\/cancers15092584","article-title":"Current Approaches for the Curative-Intent Surgical Treatment of Pancreatic Ductal Adenocarcinoma","volume":"15","author":"S\u0142odkowski","year":"2023","journal-title":"Cancers (Basel)"},{"key":"2025082802323644000_18.4.e264212.5","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1155233","article-title":"A case report of surgical resection treatment for complete remission after chemotherapy for advanced pancreatic cancer","volume":"13","author":"Zhang","year":"2023","journal-title":"Front Oncol"},{"key":"2025082802323644000_18.4.e264212.6","doi-asserted-by":"crossref","first-page":"4174","DOI":"10.3390\/cancers15164174","article-title":"Surgical Considerations for Neoadjuvant Therapy for Pancreatic Adenocarcinoma","volume":"15","author":"Jain","year":"2023","journal-title":"Cancers (Basel)"},{"key":"2025082802323644000_18.4.e264212.7","article-title":"Evaluation of Short- and Long-Term Outcomes After Resection in Patients with Locally Advanced versus (Borderline) Resectable Pancreatic Cancer","volume":"279","author":"Brada","year":"2024","journal-title":"Ann Surg"},{"key":"2025082802323644000_18.4.e264212.8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1011923"},{"key":"2025082802323644000_18.4.e264212.9","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)00172-8"},{"key":"2025082802323644000_18.4.e264212.10","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1001\/jamaoncol.2021.0057","article-title":"Association of Ablative Radiation Therapy With Survival Among Patients With Inoperable Pancreatic Cancer","volume":"7","author":"Reyngold","year":"2021","journal-title":"JAMA Oncol"},{"key":"2025082802323644000_18.4.e264212.11","doi-asserted-by":"crossref","DOI":"10.1148\/radiol.233051","article-title":"The #HOPE4LIVER Single-Arm Pivotal Trial for Histotripsy of Primary and Metastatic Liver Tumors","volume":"312","author":"Mendiratta-Lala","year":"2024","journal-title":"Radiology"},{"key":"2025082802323644000_18.4.e264212.12","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1001\/jama.2021.18859","article-title":"Incidence of Pancreatic Cancer by Age and Sex in the US, 2000-2018","volume":"326","author":"Gaddam","year":"2021","journal-title":"JAMA"},{"key":"2025082802323644000_18.4.e264212.13","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.2217\/fon-2023-0256","article-title":"A phase II study of neoadjuvant liposomal irinotecan with 5-FU and oxaliplatin (NALIRIFOX) in pancreatic adenocarcinoma","volume":"19","author":"Singhal","year":"2023","journal-title":"Future Oncol"},{"key":"2025082802323644000_18.4.e264212.14","doi-asserted-by":"crossref","first-page":"113430","DOI":"10.1016\/j.ejca.2023.113430","article-title":"Perioperative NALIRIFOX in patients with resectable pancreatic ductal adenocarcinoma: The open-label, multicenter, phase II nITRO trial","volume":"196","author":"Melisi","year":"2024","journal-title":"Eur J Cancer"},{"key":"2025082802323644000_18.4.e264212.15","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1001\/jamaoncol.2024.1930","article-title":"Pancreatic Cancer Surveillance and Survival of High-Risk Individuals","volume":"10","author":"Blackford","year":"2024","journal-title":"JAMA Oncol"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2024-264212","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T09:32:47Z","timestamp":1756373567000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2024-264212"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":15,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,4,17]]},"published-print":{"date-parts":[[2025,4]]}},"alternative-id":["10.1136\/bcr-2024-264212"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2024-264212","relation":{},"ISSN":["1757-790X"],"issn-type":[{"type":"electronic","value":"1757-790X"}],"subject":[],"published":{"date-parts":[[2025,4]]}}}